Pioneering new horizons in immunology to deliver life-changing therapies.
Our lead program barzolvolimab is a humanized monoclonal antibody inhibitor of KIT, a key receptor tyrosine kinase required for the function and survival of mast cells, which play a central role in the onset and progression of many severe inflammatory, allergic and autoimmune diseases. By targeting a core pathological driver of these diseases, we have designed barzolvolimab with the potential to be a best-in-class treatment option and improve the lives of patients.
Videos
Learn more about what we are working on at Celldex.
Our Science
Driven by our deep and longstanding experience developing antibody-based immunotherapies, Celldex’s proprietary antibody programs and technologies are supported by robust in-house capabilities, enabling the optimized discovery and development of innovative scientific programs.
Clinical Trials
Get more information on Celldex’s ongoing clinical studies, including information about how to enroll.
